NCT01179152

Brief Summary

During the second week of September( week 38 of the year)there are recorded data of exacerbation of asthma all over the world, including Israel. A short preventive treatment of 6 weeks may reduce asthma exacerbation in children,reduce primary care and ER visiting and hospitalization.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
225

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Sep 2010

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 9, 2010

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 11, 2010

Completed
21 days until next milestone

Study Start

First participant enrolled

September 1, 2010

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2011

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2012

Completed
Last Updated

March 19, 2012

Status Verified

March 1, 2012

Enrollment Period

1.1 years

First QC Date

August 9, 2010

Last Update Submit

March 16, 2012

Conditions

Keywords

asthma, september epidemic, children, preventive

Outcome Measures

Primary Outcomes (1)

  • reduction of asthma exacerbation during the study period

    less asthma exacerbation

    An average time of 8 weeks

Secondary Outcomes (1)

  • less primary care physician visits

    An average time of 8 weeks

Study Arms (3)

Budicort

ACTIVE COMPARATOR

75 children will receive treatment with Budicort 200 mcg

Drug: Budesonide turbuhaler, Budesonide+Formoterol turbuhaler

Symbicort

ACTIVE COMPARATOR

75 children will receive treatment with Symbicort 160 mcg

Drug: Budesonide turbuhaler, Budesonide+Formoterol turbuhaler

counselling

NO INTERVENTION

75 children who will not treated as their request but will be folowedup

Drug: Budesonide turbuhaler, Budesonide+Formoterol turbuhaler

Interventions

Budesonide 200 mcg turbuhaler or Budesonide+Formoterol 160mcg turbuhaler

Also known as: Budesonide turbuhaler, Budesonide+Formoterol turbuhaler
BudicortSymbicortcounselling

Eligibility Criteria

Age6 Years - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • age : 6-18 years suffering from asthma asthma exacerbation during 1/9/2009-15/10/2009

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Meir Medical Center

Kfar Saba, Israel

RECRUITING

Related Publications (1)

  • Johnston NJ, Johnston SL, Duncan JM, Greene JM,Keith PK,Roy M, Wsaerman S, Sears MR. The september epidemic of asthma exacerbation in children:a search for etiology. J allergy Clin Immunol 2005,115;132-8 Scheuerman O, Meyerowitch J, Marcus N, Hoffer V, Batt E , Garty B-Z. The september epidemic of asthma in Israel. J of Asthma 2009;46;652-5 Johnston NW, Mandhane PJ, Dai J, Duncan JM, Greene JM,Lambert K, Sears Mr. Attenuation of the september epidemic of asthma exacerbation in children: A randomized controlled trial of montelukast added to usual therapy. Pediatrics;120;e702-e712.

    BACKGROUND

MeSH Terms

Conditions

Asthma

Condition Hierarchy (Ancestors)

Bronchial DiseasesRespiratory Tract DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Study Officials

  • Avner He Cohen, Dr

    Clalit Health Services

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Avner He Cohen, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 9, 2010

First Posted

August 11, 2010

Study Start

September 1, 2010

Primary Completion

October 1, 2011

Study Completion

October 1, 2012

Last Updated

March 19, 2012

Record last verified: 2012-03

Locations